In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Vosoritide | Natural fragment Teriparatide (PTH 1-34) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 306 | 2,709 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 90 (90 in people) | 209 (168 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 16 · 12 active | 168 · 15 active30 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Voxzogo says: “Pediatric achondroplasia with open epiphyses”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Vosoritide | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletal | 14113011 | 2,2281286 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
| Adverse eventsWhole body | 6969 | 16313726 |
|---|
| PharmacokineticsPharmacology | 15123 | 30273 |
|---|
| Receptor activity and mechanismPharmacology | 15132 | 46151516 |
|---|
| Quality of lifeWhole body | 1515 | 1313 |
|---|
| Exercise and physical functionMusculoskeletal | 99 | 1818 |
|---|
| Linear growthMusculoskeletal | 1111 | 11 |
|---|
| MortalityWhole body | 66 | 312 |
|---|
| Body weightMetabolic and weight | 33 | 1028 |
|---|
| Growth hormone and IGF-1Endocrine and hormones | 66 | 11 |
|---|
| Treatment adherence and retentionWhole body | 11 | 66 |
|---|
| Skin and hairSkin and wound | 11 | 55 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Vosoritide | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: difference from placebo, in cm/year | 1.57 cm/year Adjusted mean difference in annualized growth velocity Dose studied: 15 μg/kg once daily52 weeksn = 1212020 | No comparable result 701 randomized-trial results measure it in another way or another unit. |
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | No randomized trial result 9 results from other study designs. | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks Dose studied: 20 μg every day78 weeksn = 1712017 |
| Linear growthMusculoskeletalCompared as: value in the arm that got the peptide, in cm/year | 1.95 cm/year LSM change Placebo: −0.39 cm/year 52 weeksn = 812026 | No randomized trial result 1 result from other study designs. |
| Adverse eventsMusculoskeletalCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 10% Nasopharyngitis Dose studied: 20 μg once daily12 monthsn = 4322017 |
1.57 cm/year
Adjusted mean difference in annualized growth velocity
Dose studied: 15 μg/kg once daily52 weeksn = 1212020
No comparable result
701 randomized-trial results measure it in another way or another unit.
No randomized trial result
9 results from other study designs.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
1.95 cm/year
LSM change
Placebo: −0.39 cm/year
52 weeksn = 812026
No randomized trial result
1 result from other study designs.
No comparable result
2 randomized-trial results measure it in another way or another unit.
10%
Nasopharyngitis
Dose studied: 20 μg once daily12 monthsn = 4322017
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 16 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
BioMarin Pharmaceutical121 participants12 Dec 2016 to 30 Oct 2019
Achondroplasia
BioMarin Pharmaceutical160 participants20 Apr 2026 to est. Sept 2029
Achondroplasia
BioMarin Pharmaceutical140 participants20 Jun 2025 to est. Oct 2044
Hypochondroplasia
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.